<?xml version="1.0" encoding="UTF-8"?>
<gtr:projectOverview xmlns:gtr="http://gtr.ukri.org/api"><gtr:projectComposition><gtr:collaborations/><gtr:leadResearchOrganisation url="http://gtr.ukri.org:80/organisation/1F79B37B-211A-44C1-A702-B351C3F566B0"><gtr:id>1F79B37B-211A-44C1-A702-B351C3F566B0</gtr:id><gtr:name>Innova Biosciences Ltd</gtr:name><gtr:address><gtr:line1>BABRAHAM HALL, BABRAHAM , CAMBRIDGE</gtr:line1><gtr:city>CAMBRIDGESHIRE</gtr:city><gtr:postCode>CB22 3AT</gtr:postCode><gtr:region>East of England</gtr:region></gtr:address><gtr:typeInd>P</gtr:typeInd></gtr:leadResearchOrganisation><gtr:organisationRoles><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/1F79B37B-211A-44C1-A702-B351C3F566B0" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:type="gtr:organisationParticipantRole"><gtr:id>1F79B37B-211A-44C1-A702-B351C3F566B0</gtr:id><gtr:name>Innova Biosciences Ltd</gtr:name><gtr:address><gtr:line1>BABRAHAM HALL, BABRAHAM , CAMBRIDGE</gtr:line1><gtr:city>CAMBRIDGESHIRE</gtr:city><gtr:postCode>CB22 3AT</gtr:postCode><gtr:region>East of England</gtr:region></gtr:address><gtr:roles><gtr:role><gtr:name>PARTICIPANT</gtr:name></gtr:role><gtr:role><gtr:name>LEAD_PARTICIPANT</gtr:name></gtr:role></gtr:roles><gtr:offerGrant>206949.0</gtr:offerGrant><gtr:projectCost>459887.0</gtr:projectCost></gtr:organisationRole></gtr:organisationRoles><gtr:personRoles><gtr:personRole url="http://gtr.ukri.org:80/person/ECFA4BCD-AB04-464C-8846-CE0884A18F93"><gtr:id>ECFA4BCD-AB04-464C-8846-CE0884A18F93</gtr:id><gtr:firstName>Nick</gtr:firstName><gtr:surname>Gee</gtr:surname><gtr:roles><gtr:role><gtr:name>PROJECT_MANAGER</gtr:name></gtr:role></gtr:roles></gtr:personRole></gtr:personRoles><gtr:project url="http://gtr.ukri.org:80/projects?ref=720092"><gtr:id>6675D198-28C2-4B5C-BD6D-D188BFDDE3CE</gtr:id><gtr:title>Easy-to-Use Nanoparticle Conjugation Kits</gtr:title><gtr:status>Closed</gtr:status><gtr:grantCategory>GRD Development of Prototype</gtr:grantCategory><gtr:grantReference>720092</gtr:grantReference><gtr:abstractText>Innova Biosciences develops technologies that allow coloured or other detectable substances
(?labels?) to be attached irreversibly to an antibody to form a hybrid molecule called either an
?antibody conjugate? or a ?labelled antibody?. Innova uses uniquely simple processes that save
operator time, improve yield of antibody conjugates and minimise batch-to-batch variation.
Labelled antibodies are an integral part of modern biological research and medical diagnosis.
The growing diagnostic market requires antibodies to be attached to nanoparticles (gold or
latex particles for instance), but the traditional methods for creating these particular hybrid
reagents are not straightforward; often there is poor reproducibility, unwanted aggregation and
reagent instability. These problems reflect the intrinsic properties of nanoparticles and also the
fact that the antibodies are attached by relatively weak bonds using ?passive? adsorption
processes.
Innova will develop ultra-stable derivatives of nanoparticles with a special stabilising surface
coat and new methods of nanoparticle labelling technologies, to allow irreversible attachment
of antibodies. Methods for orienting antibodies favourably on the surface will also be
developed to allow the best possible performance of the antibody-nanoparticle conjugate in
diagnostic applications.
Sold in easy-to-use kit formats, the nanoparticle linking systems will be used for evaluation
within the research labs of diagnostics companies. Such labs are receptive to new technologies
that can accelerate development work and enhance the performance of reagents and sensitivity
of diagnostic tests. In parallel, Innova will develop processes for making large quantities (up
to 50 litres) of ultra-stable nanoparticles to support bulk manufacturing of Point of Care
devices by diagnostics companies.</gtr:abstractText><gtr:fund><gtr:end>2014-02-28</gtr:end><gtr:funder url="http://gtr.ukri.org:80/organisation/E18E2F0F-AC7D-4E02-9559-669F7C8FEC74"><gtr:id>E18E2F0F-AC7D-4E02-9559-669F7C8FEC74</gtr:id><gtr:name>Innovate UK</gtr:name></gtr:funder><gtr:start>2012-03-01</gtr:start><gtr:type>INCOME_ACTUAL</gtr:type><gtr:valuePounds>206949</gtr:valuePounds></gtr:fund><gtr:output><gtr:artisticAndCreativeProductOutputs/><gtr:collaborationOutputs/><gtr:disseminationOutputs/><gtr:exploitationOutputs/><gtr:furtherFundingOutputs/><gtr:impactSummaryOutputs/><gtr:intellectualPropertyOutputs/><gtr:otherResearchOutputs/><gtr:policyInfluenceOutputs/><gtr:productOutputs/><gtr:researchDatabaseAndModelOutputs/><gtr:researchMaterialOutputs/><gtr:softwareAndTechnicalProductOutputs/><gtr:spinOutOutputs/></gtr:output><gtr:publications/><gtr:identifiers><gtr:identifier type="RCUK">720092</gtr:identifier></gtr:identifiers><gtr:healthCategories/><gtr:researchActivities/><gtr:researchSubjects/><gtr:researchTopics><gtr:researchTopic><gtr:id>D05BC2E0-0345-4A3F-8C3F-775BC42A0819</gtr:id><gtr:text>Unclassified</gtr:text></gtr:researchTopic></gtr:researchTopics><gtr:rcukProgrammes/></gtr:project></gtr:projectComposition></gtr:projectOverview>